Sight Sciences, Inc. (SGHT) Bundle
Understanding Sight Sciences, Inc. (SGHT) Revenue Streams
Understanding Sight Sciences, Inc.’s Revenue Streams
As of September 30, 2024, the total revenue for Sight Sciences, Inc. was $60.8 million, which represents a decrease of 2.4% compared to $62.3 million in the same period of the previous year. This decline is primarily attributed to significant changes in the revenue contributions from its two main segments.
Breakdown of Primary Revenue Sources
- Surgical Glaucoma Revenue: For the nine months ended September 30, 2024, revenue from this segment was $57.1 million, a slight decrease of less than 0.1% from $57.2 million in the prior year.
- Dry Eye Revenue: This segment generated $3.7 million, a significant decline of 28.9% compared to $5.1 million in the previous year.
| Revenue Source | 2024 Revenue ($m) | 2023 Revenue ($m) | Change ($m) | Percentage Change (%) |
|---|---|---|---|---|
| Surgical Glaucoma | 57.1 | 57.2 | -0.1 | -0.0 |
| Dry Eye | 3.7 | 5.1 | -1.4 | -28.9 |
| Total Revenue | 60.8 | 62.3 | -1.5 | -2.4 |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the Surgical Glaucoma segment was -0.0%, whereas the Dry Eye segment experienced a substantial decline of 28.9%. This reflects a strategic shift in focus towards achieving reimbursed market access for Dry Eye products, impacting new customer acquisition and overall sales.
Contribution of Different Business Segments to Overall Revenue
For the nine months ended September 30, 2024, the contribution to total revenue was as follows:
- Surgical Glaucoma: 94.0% of total revenue
- Dry Eye: 6.0% of total revenue
Analysis of Significant Changes in Revenue Streams
The decrease in revenue from the Dry Eye segment is primarily due to fewer new customers being added during the period, which affected sales of SmartHub and SmartLids. The strategic focus on reimbursement rather than cash-pay models has also led to lower overall sales volumes in this segment. In contrast, the Surgical Glaucoma segment saw a marginal increase in revenue attributed to higher unit sales driven by increased utilization.
Overall, while the Surgical Glaucoma segment remains stable, the Dry Eye segment faces challenges that could continue to impact its revenue generation in the near term.
A Deep Dive into Sight Sciences, Inc. (SGHT) Profitability
A Deep Dive into Sight Sciences, Inc.'s Profitability
Gross Profit: For the three months ended September 30, 2024, the total gross profit was $16.9 million, a decrease of $0.4 million from $17.3 million in the prior year comparable period.
Gross Margin: The gross margin for the three months ended September 30, 2024 was 83.9%, down from 86.6% in the prior year. The gross margin in the Surgical Glaucoma segment was 86.8%, compared to 89.1% the previous year. In the Dry Eye segment, gross margin fell to 47.7% from 57.4%.
Operating Profit: The loss from operations for the three months ended September 30, 2024 was $(11.2 million), an improvement from a loss of $(13.4 million) in the prior year.
Net Profit Margin: The net loss for the three months ended September 30, 2024 was $(11.1 million), with a net loss margin of approximately (55.0%), compared to (65.4%) in the prior year.
Trends in Profitability Over Time
For the nine months ended September 30, 2024, the gross profit was $51.7 million, which is a decrease of $1.5 million from $53.2 million in the prior year. The gross margin for the nine months ended September 30, 2024 was 85.1%, slightly down from 85.4% in the prior year.
The loss from operations for the nine months was $(38.6 million), an improvement from $(46.2 million) for the same period in 2023. The net loss for the nine months ended September 30, 2024 was $(39.7 million), compared to $(44.9 million) in the prior year.
Comparison of Profitability Ratios with Industry Averages
| Metric | Sight Sciences, Inc. (2024) | Industry Average |
|---|---|---|
| Gross Margin | 83.9% | 70.0% |
| Operating Margin | (55.0%) | (30.0%) |
| Net Margin | (54.0%) | (25.0%) |
Analysis of Operational Efficiency
The total operating expenses for the three months ended September 30, 2024 were $28.1 million, down from $30.7 million in the prior year, reflecting a decrease of 8.5%.
Research and Development (R&D) expenses for the three months ended September 30, 2024 were $4.7 million, an increase of 12.0% from $4.2 million. Selling, General, and Administrative (SG&A) expenses were $23.4 million, a decrease of $3.1 million from $26.5 million.
The total gross profit for the nine months ended September 30, 2024 was $51.7 million, with a gross margin of 85.1%. This reflects a decrease in gross margin in both segments due to higher overhead costs per unit as a result of lower production volumes.
| Segment | Gross Profit (2024) | Gross Margin (2024) | Gross Profit (2023) | Gross Margin (2023) |
|---|---|---|---|---|
| Surgical Glaucoma | $50.0 million | 87.6% | $50.4 million | 88.1% |
| Dry Eye | $1.7 million | 45.8% | $2.9 million | 55.4% |
Debt vs. Equity: How Sight Sciences, Inc. (SGHT) Finances Its Growth
Debt vs. Equity: How Sight Sciences, Inc. Finances Its Growth
Debt Levels
As of September 30, 2024, the total debt reported was $35.0 million under the Hercules Term Loan Agreement. The outstanding debt is classified as long-term, with a balance of $34.2 million reported at amortized cost. The company has also had a decrease in interest expense, which was $3.5 million for the nine months ended September 30, 2024, down from $4.1 million in the same period the previous year.
Debt-to-Equity Ratio
The company's debt-to-equity ratio as of September 30, 2024, can be calculated based on total liabilities and stockholders' equity. The total stockholders' equity was $94.96 million. Given the total liabilities of $143.60 million, the debt-to-equity ratio is approximately 1.51 (calculated as total debt divided by total equity). This ratio is higher than the industry average, which typically ranges from 0.5 to 1.0.
Recent Debt Issuances
In January 2024, the company entered into a Loan and Security Agreement with Hercules Capital, which provides for a senior secured term loan facility of up to $65.0 million. The initial loan of $35.0 million was used to discharge previous indebtedness. The Hercules Loan Agreement includes additional tranches available upon achieving certain performance milestones.
Credit Ratings
The company has not publicly disclosed a specific credit rating; however, it operates under the terms of the Hercules Loan Agreement, which typically reflects a higher risk due to its status as a growth-stage company.
Balancing Debt Financing and Equity Funding
Since inception, the company has raised approximately $402.4 million through private placements and public offerings, indicating a strong reliance on equity financing. The balance between debt and equity funding is crucial, especially as the company focuses on scaling operations while managing its cash flow, which currently stands at $118.6 million.
| Financial Metric | Amount |
|---|---|
| Total Debt | $35.0 million |
| Total Equity | $94.96 million |
| Debt-to-Equity Ratio | 1.51 |
| Interest Expense (2024) | $3.5 million |
| Cash and Cash Equivalents | $118.6 million |
| Funds Raised (Since Inception) | $402.4 million |
Assessing Sight Sciences, Inc. (SGHT) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios (Liquidity Positions)
The current ratio as of September 30, 2024, is calculated as follows:
- Current Assets: $140.5 million
- Current Liabilities: $13.8 million
- Current Ratio: 10.16
The quick ratio is similarly strong:
- Quick Assets (Current Assets - Inventory): $134.4 million
- Quick Ratio: 9.72
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, stands at:
- Working Capital: $126.7 million
As of September 30, 2024, this reflects an increase from the previous year, indicating improved liquidity management.
Cash Flow Statements Overview
The following table summarizes the cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):
| Cash Flow Category | 2024 | 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(18,892) | $(40,700) |
| Net Cash Used in Investing Activities | $(248) | $(527) |
| Net Cash (Used in) Provided by Financing Activities | $(425) | $728 |
| Net Change in Cash and Cash Equivalents | $(19,565) | $(40,499) |
Operating Cash Flow Trends
Operating cash flow is primarily impacted by:
- Net Loss: $(39.7 million)
- Non-cash Charges: $15.6 million
- Net Change in Operating Assets and Liabilities: $5.2 million
Investing Cash Flow Trends
Investing activities have been minimal:
- Cash used for property and equipment purchases: $(248,000)
Financing Cash Flow Trends
Financing activities show a net cash outflow:
- Repayment of debts: $(35.4 million)
- Net proceeds from Hercules Loan Agreement: $34.5 million
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company has:
- Cash and Cash Equivalents: $118.6 million
- Outstanding Debt under Hercules Term Loan: $35.0 million
- Accumulated Deficit: $(334.5 million)
Despite an accumulated deficit, the strong liquidity ratios suggest that the company is well-positioned to meet its short-term obligations.
Is Sight Sciences, Inc. (SGHT) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will examine key valuation metrics such as the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, alongside stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The price-to-earnings (P/E) ratio for the company is currently N/A due to the company reporting a net loss. This indicates that the company is not generating positive earnings at this time, making the P/E ratio an unreliable metric for valuation.
Price-to-Book (P/B) Ratio
The price-to-book (P/B) ratio is calculated as follows:
- Book Value per Share: Total Stockholders' Equity / Total Shares Outstanding
- Total Stockholders' Equity (as of September 30, 2024): $94.957 million
- Total Shares Outstanding: 50,398,148
- Book Value per Share: $1.88
- Current Stock Price (as of September 30, 2024): $5.62
- P/B Ratio: 3.00
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) is calculated as follows:
- Market Capitalization: $282.55 million (Current Stock Price Total Shares Outstanding)
- Total Debt: $35.0 million (Hercules Loan Agreement)
- Cash and Cash Equivalents: $118.564 million
- Enterprise Value: $199.986 million (Market Capitalization + Total Debt - Cash)
EBITDA for the last twelve months (TTM) is N/A due to the company's losses.
Stock Price Trends
The stock price has shown fluctuations over the past 12 months:
- 12-Month High: $8.50
- 12-Month Low: $4.00
- Current Stock Price as of September 30, 2024: $5.62
Dividend Yield and Payout Ratios
As of September 30, 2024, the company does not pay any dividends, resulting in a dividend yield of 0%. The payout ratio is also N/A due to the absence of dividends and net income.
Analyst Consensus
Analyst consensus on the stock valuation is as follows:
- Buy: 2 analysts
- Hold: 5 analysts
- Sell: 1 analyst
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 3.00 |
| EV/EBITDA Ratio | N/A |
| 12-Month High | $8.50 |
| 12-Month Low | $4.00 |
| Current Stock Price | $5.62 |
| Dividend Yield | 0% |
| Analyst Consensus (Buy) | 2 |
| Analyst Consensus (Hold) | 5 |
| Analyst Consensus (Sell) | 1 |
Key Risks Facing Sight Sciences, Inc. (SGHT)
Key Risks Facing Sight Sciences, Inc.
The financial health of the company is influenced by various internal and external risk factors. Understanding these risks is crucial for investors.
Industry Competition
The company operates in a competitive landscape, particularly in the medical device sector. Competitors may introduce innovative products that could capture market share. For instance, the company reported a 28.9% decrease in Dry Eye revenue, primarily attributed to fewer new customers added during the period.
Regulatory Changes
Changes in healthcare regulations can impact operational costs and market access. The company is focusing on achieving reimbursed market access for its Dry Eye segment, which represents a strategic shift in its commercial strategy.
Market Conditions
Fluctuations in market demand can significantly affect sales. The company's total revenue for the nine months ended September 30, 2024, was $60.8 million, a decrease of 2.4% compared to the prior year.
Operational Risks
Operational risks include production inefficiencies and supply chain disruptions. The cost of goods sold for the three months ended September 30, 2024, was $3.3 million, an increase of $0.6 million from the prior year.
Financial Risks
The company faces financial risks such as high operational expenses and debt obligations. For the three months ended September 30, 2024, the company reported selling, general, and administrative expenses of $23.4 million, a decrease from the prior year but still significant.
Strategic Risks
Strategic risks involve the potential failure to execute business plans effectively. The decrease in gross margin for the Dry Eye segment from 57.4% in the third quarter of 2023 to 47.7% in 2024 reflects challenges in maintaining profitability.
Mitigation Strategies
To address these risks, the company has implemented various strategies. The focus on reimbursed market access aims to stabilize revenue streams while managing costs effectively. As of September 30, 2024, the company had cash and cash equivalents of $118.6 million, providing a buffer against financial uncertainties.
| Risk Factor | Details | Impact |
|---|---|---|
| Industry Competition | Introduction of innovative products by competitors | Potential loss of market share |
| Regulatory Changes | Changes in healthcare regulations | Increased operational costs |
| Market Conditions | Fluctuations in demand | Decrease in total revenue |
| Operational Risks | Production inefficiencies and supply chain issues | Increased cost of goods sold |
| Financial Risks | High operational expenses and debt obligations | Net loss and comprehensive loss of $39.7 million |
| Strategic Risks | Failure to execute business plans effectively | Decrease in gross margin |
Future Growth Prospects for Sight Sciences, Inc. (SGHT)
Future Growth Prospects for Sight Sciences, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include:
- Product Innovations: The company has continued to enhance its product offerings, particularly in the Surgical Glaucoma segment, which generated $57.1 million in revenue for the nine months ended September 30, 2024, showing a decrease of less than 0.1% from the previous year.
- Market Expansions: The focus has shifted towards achieving reimbursed market access for its Dry Eye segment, which is expected to drive future growth.
- Acquisitions: While specific acquisitions were not detailed, the company is positioned to explore strategic acquisitions to enhance its market presence and product range in the ophthalmology sector.
Future Revenue Growth Projections and Earnings Estimates
The overall revenue for the nine months ended September 30, 2024, was $60.8 million, a decrease of 2.4% from the previous year. The Surgical Glaucoma segment accounted for 94.0% of total revenue, while the Dry Eye segment represented 6.0%. Future projections suggest a potential recovery in revenue, driven by increased unit utilization and market penetration strategies.
| Segment | Revenue (9M 2024) | Percentage of Total Revenue | Change from Previous Year |
|---|---|---|---|
| Surgical Glaucoma | $57.1 million | 94.0% | Less than 0.1% |
| Dry Eye | $3.7 million | 6.0% | -28.9% |
| Total | $60.8 million | 100% | -2.4% |
Strategic Initiatives or Partnerships That May Drive Future Growth
The company has entered into a Loan and Security Agreement with Hercules Capital for a total of $65 million, which includes an initial tranche of $35 million. This funding is expected to support ongoing operations and potential expansion efforts. Additionally, the company is focused on enhancing its reimbursement strategies for its products, which is critical for growth in the Dry Eye segment.
Competitive Advantages That Position the Company for Growth
The company benefits from a robust product pipeline and established market presence in the ophthalmology field. The Surgical Glaucoma segment's gross margin was reported at 87.6%, indicating strong profitability. Furthermore, the recent changes in Medicare coverage policies, which are favorable for the company's offerings, position it well for future growth.
Sight Sciences, Inc. (SGHT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Sight Sciences, Inc. (SGHT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Sight Sciences, Inc. (SGHT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Sight Sciences, Inc. (SGHT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.